CD44 and breast cancer: We treated HCC1500, CAL-51 and MDA-MB-231 with typical chemotherapies for breast cancer, 5-FU, PTX, and DOX, for 5 days and measured CSC marker expressing cells CD133+/CD44+ by flow cytometry and also by measuring total cell survival upon these chemotherapy reagent treatments.